Business Description
Anteris Technologies Global Corp
NAICS : 325413
SIC : 3844
ISIN : US03675P1021
Total Employee Number:
174Description
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 75.69 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 33.53 | |||||
Beneish M-Score | -3.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -39.4 | |||||
3-Year EBITDA Growth Rate | -5.8 | |||||
3-Year EPS without NRI Growth Rate | -2.3 | |||||
3-Year FCF Growth Rate | -0.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 115.79 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.96 | |||||
9-Day RSI | 58.25 | |||||
14-Day RSI | 61.13 | |||||
3-1 Month Momentum % | 73.96 | |||||
6-1 Month Momentum % | 77.82 | |||||
12-1 Month Momentum % | 142.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.93 | |||||
Quick Ratio | 20.93 | |||||
Cash Ratio | 20.64 | |||||
Days Inventory | 233.57 | |||||
Days Sales Outstanding | 54.15 | |||||
Days Payable | 4606.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.1 | |||||
Shareholder Yield % | -34.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.28 | |||||
Operating Margin % | -5206 | |||||
Net Margin % | -5148.78 | |||||
EBITDA Margin % | -5021.02 | |||||
FCF Margin % | -4693.79 | |||||
OCF Margin % | -4591.79 | |||||
ROE % | -136.26 | |||||
ROA % | -109.43 | |||||
ROIC % | -1101.14 | |||||
3-Year ROIIC % | -1530.64 | |||||
ROC (Joel Greenblatt) % | -1344.42 | |||||
ROCE % | -131.72 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 229.53 | |||||
PB Ratio | 3.45 | |||||
Price-to-Tangible-Book | 3.45 | |||||
EV-to-EBIT | -7.2 | |||||
EV-to-EBITDA | -7.34 | |||||
EV-to-Revenue | 368.33 | |||||
EV-to-FCF | -7.85 | |||||
| Price-to-Net-Current-Asset-Value | 3.55 | |||||
| Price-to-Net-Cash | 3.6 | |||||
Earnings Yield (Greenblatt) % | -13.89 | |||||
FCF Yield % | -9.04 |
GF Value™
Anteris Technologies Global Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anteris Technologies Global Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-03 | In 160 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 46 days | ||
| First quarter earnings results for 2026 | 2026-05-12 | 6.51 (-2.11%) | ||
| Barclays 28th Annual Healthcare Conference | 2026-03-10 13:30 | 5.93 (-1.98%) | ||
| TD Cowen 46th Annual Healthcare Conference | 2026-03-02 15:10 | 6.51 (+5.00%) | ||
| Annual report for 2025 | 2026-02-26 | 6.27 (+0.16%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 6.27 (+0.16%) | ||
| General meeting for 2025 | 2025-12-03 | 4.18 (+2.96%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 3.78 (-4.06%) |
Show
Entries
Guru Commentaries on NAS:AVR
No articles.
Press Release
Articles on Anteris Technologies Global Corp
No articles.